UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number - 001-40133 ENVOY MEDICAL, INC. | --- | --- | |----------------------------------------------------------------------------|--------------- ...

Exhibit 99.1 Envoy Medical Reports Third Quarter 2024 Results and Other Exciting Events FDA approval to begin pivotal trial of fully implanted cochlear implant and AMA approval of CPT codes for the Company's already FDA-approved fully implanted middle ear implant are two of the exciting developments for the growing company WHITE BEAR LAKE, Minn., Nov. 14, 2024 (GLOBE NEWSWIRE) -- Envoy Medical®, Inc. ("Envoy Medical") (Nasdaq: COCH), a revolutionary hearing health company focused on fully implanted hearing ...

The Acclaim® Fully Implanted Cochlear Implant is differentiated from existing cochlear implants and may offer new option for hearing loss patients WHITE BEAR LAKE, Minnesota, Nov. 01, 2024 (GLOBE NEWSWIRE) --  Envoy Medical®, Inc. (“Envoy Medical”) (NASDAQ: “COCH”), a hearing health company focused on fully implanted hearing systems, today announces that its Investigational Device Exemption (IDE) application for its pivotal study of the Acclaim® Fully Implanted Cochlear Implant has been approved by the U.S ...

Core Viewpoint - Envoy Medical, Inc. is set to present a corporate overview at the LD Micro Main Event XVII, highlighting its focus on fully implanted hearing systems and innovative products in the hearing health sector [1][2]. Company Overview - Envoy Medical specializes in hearing health, particularly in fully implanted hearing systems, with products like the Esteem fully implanted active middle ear implant (FI-AMEI) and the Acclaim Cochlear Implant [1][5]. - The Esteem FI-AMEI is the only FDA-approved fully implanted hearing device for adults with moderate to severe sensorineural hearing loss, providing continuous hearing without the need for external components [3]. - The Acclaim Cochlear Implant is an investigational device designed for severe to profound sensorineural hearing loss, leveraging the ear's natural anatomy for sound capture [5]. Product Details - The Esteem FI-AMEI offers 24/7 hearing capability, is invisible, and does not require external components or cleaning, distinguishing it from traditional hearing aids [3]. - The Acclaim Cochlear Implant received Breakthrough Device Designation from the FDA in 2019, marking it as a significant advancement in hearing technology [5]. Event Information - David R. Wells, the Chief Financial Officer, will present on October 29, 2024, at 12:00 PM Pacific Time, and will be available for one-on-one meetings with registered investors [2][3].

Growing Portfolio of Patents Further Advances the Company's Mission to Develop Fully Implanted Devices for Those Suffering from Significant Hearing Loss WHITE BEAR LAKE, Minnesota, Sept. 16, 2024 (GLOBE NEWSWIRE) -- Envoy Medical®, Inc. ("Envoy Medical") (NASDAQ: "COCH"), a hearing health company focused on fully implanted hearing systems, today announces it has been awarded another patent from the US Patent & Trademark Office for its fully implanted devices. On September 3rd, the Company was issued Patent ...

Exhibit 99.1 Envoy Medical Reports Second Quarter 2024 Results and Provides Business Update Company continues to make significant progress towards disrupting the existing cochlear implant industry with its investigational, breakthrough fully implanted Acclaim cochlear implant; Maintains goal of starting Pivotal Clinical Trial by end of the year WHITE BEAR LAKE, Minn., August 12, 2024 (GLOBE NEWSWIRE) -- Envoy Medical, Inc. ("Envoy Medical") (Nasdaq: COCH), a revolutionary hearing health company focused on f ...

Company continues to make significant progress towards disrupting the existing cochlear implant industry with its investigational, breakthrough fully implanted Acclaim® cochlear implant; Maintains goal of starting Pivotal Clinical Trial by end of the year WHITE BEAR LAKE, Minn., Aug. 12, 2024 (GLOBE NEWSWIRE) -- Envoy Medical®, Inc. ("Envoy Medical") (Nasdaq: COCH), a revolutionary hearing health company focused on fully implanted hearing devices, today announces its corporate and financial results for the ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number - 001-40133 ENVOY MEDICAL, INC. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation or ...

The Acclaim CI is designed to address severe to profound sensorineural hearing loss that is not adequately addressed by hearing aids. The Acclaim CI is expected to be indicated for adults who have been deemed adequate candidates by a qualified physician. WHITE BEAR LAKE, MN, July 01, 2024 (GLOBE NEWSWIRE) -- Envoy Medical®, Inc. ("Envoy Medical") (Nasdaq: COCH), a revolutionary hearing health company focused on fully implanted hearing systems, announces that FTSE Russell has selected the Company's shares fo ...

About the Fully Implanted Acclaim® Cochlear Implant The Acclaim CI is designed to address severe to profound sensorineural hearing loss that is not adequately addressed by hearing aids. The Acclaim CI is expected to be indicated for adults who have been deemed adequate candidates by a qualified physician. CAUTION The fully implanted Acclaim Cochlear Implant is an investigational device. Limited by Federal (or United States) law to investigational use. *Once activated, the external Esteem FI-AMEI Personal Pr ...